BeiGene | Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Beigene Study ID

BGB-LC-202

ClinicalTrials.gov ID

NCT05577702

China Drug Trials ID

CTR20222760

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents